If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksWilmington Regulatory News (WIL)

Share Price Information for Wilmington (WIL)

Share Price is delayed by 15 minutes
Get Live Data
263.00    -15.00 (-5.40%)
Bid:
274.00
Ask:
277.00
Spread: 3.00 (1.095%)
Market Cap: £235.53m
WIL Live PriceLast checked at - London Stock Exchange

Intraday Wilmington Share Chart

Wilmington plc Pre-close Trading Update

28 Jun 2019 07:00

RNS Number : 7299D
Wilmington PLC
28 June 2019
 

28 June 2019

 

Wilmington plc

('Wilmington', 'the Group' or 'the Company')

Pre-close Trading Update

 

Wilmington plc, the provider of information, education and networking services in Risk & Compliance, Healthcare and Professional knowledge areas, today announces a pre-close trading update for the year to 30 June 2019.

 

Trading Update

 

The Board is pleased to announce that underlying trading is broadly in line with the full year expectations set out at the start of the financial year. After a strong Q3, with organic revenue growth levels that were in excess of those expected, Q4 is likely to be approximately flat year on year, such that full year organic revenue growth will be positive, albeit towards the lower end of the previously anticipated low single digit range. Underlying costs are similarly at the lower end of expectations and hence on a comparable basis adjusted profit before tax is expected to be in line with previous guidance.

 

These results will be impacted by the adoption in the year of the IFRS 15 revenue recognition standard. As previously disclosed at the time of the interim results announcement in February, adoption of IFRS 15 for the year to 30 June 2018 had a £0.5m negative impact on previously reported full year revenue and adjusted EBITA. It is anticipated that the corresponding impact of adoption of IFRS 15 for the year to 30 June 2019 will be slightly higher than for the prior year due mainly to growth in revenue from on-line training programmes.

 

Cashflow generation in the second half of the year has been strong and expectations for year end net debt remain unchanged. Adoption of IFRS 15 has no impact on cash or cash generation.

 

The preliminary announcement of the Group's full year results to 30 June 2019 is expected to be published on 19 September 2019.

 

Divisional Commentary

 

Organic revenue growth for the full year in the Risk & Compliance division is expected to be in line with our mid-single digit growth aspiration. Good growth momentum has continued in the main Compliance business during H2 with strong demand for both on-line courses and in-house programmes.

 

In the Healthcare division, revenue performance has continued to improve, with an expectation that full year organic revenue growth will be around 1% with a stronger second half after the 5% organic decline in H1. The improvement comes partly from new business sales performance in the UK Healthcare business, which is expected to grow by mid-single digit percentage year on year. The second half in Healthcare has also seen a strong performance in US Healthcare due in part to a record attendance at the flagship RISE Nashville event that was held in March.

 

Market conditions for the Professional businesses have proved challenging in Q4 with the Brexit delay and uncertainties over the current political climate in the UK resulting in lower demand for training from legal and accountancy clients. This is expected to result in a low single digit organic decline in revenues for the Professional division for the full year after a flat first half. Recent investments in new products and internal systems means the division is well placed to benefit when market demand improves once the political situation is resolved and there is clarity on ongoing laws and regulations.

 

Board Update

 

As announced on 16 May 2019, the Board is pleased to welcome Mark Milner who will be joining the Group as Chief Executive Officer on 1 July 2019. At the same time, Martin Morgan, currently Interim Executive Chairman will revert to his previous position as Non-executive Chairman.

 

 

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement this inside information is now considered to be in the public domain.

For further information, please contact:

 

Wilmington plc 020 7490 0049

Martin Morgan, Interim Executive Chairman

Richard Amos, Chief Financial Officer

 

FTI Consulting 020 3727 1000

Charles Palmer / Dwight Burden / Leah Dudley

 

 

Notes to Editors

Wilmington plc is the recognised knowledge leader and partner of choice for information, education and networking in Risk & Compliance, Healthcare and Professional areas. Wilmington employs close to 1,000 people and has customers in 120 countries. Wilmington plc is a premium listed company on the main market of the London Stock Exchange.

END

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTSEMFMWFUSEDM
Date   Source Headline
17th Apr 202611:20 amRNSHolding(s) in Company
15th Apr 20263:56 pmRNSBoard changes
15th Apr 202611:21 amRNSSave As You Earn Options
11th Mar 202611:00 amRNSDirector Declaration
11th Mar 202611:00 amRNSDirector Declaration
26th Feb 20267:00 amRNSHalf-year Financial Report
11th Feb 20262:44 pmRNSNotice of half year-end results
21st Jan 202611:19 amRNSNotice of Half Year Results
23rd Dec 20257:00 amRNSAppointment of Joint Corporate Broker
23rd Dec 20257:00 amRNSAppointment of Joint Corporate Broker
5th Dec 20259:56 amRNSAcquisition of Conversia completed
28th Nov 20254:23 pmRNSDirector/PDMR Shareholding
28th Nov 202511:22 amRNSAcquisition of Conversia cleared to complete
25th Nov 20259:19 amRNSResult of AGM
10th Nov 20255:54 pmRNSDirectorate change
1st Oct 20252:51 pmRNSDirector/PDMR Shareholding
1st Oct 20252:49 pmRNSDirector/PDMR Shareholding
1st Oct 20257:00 amRNSDirector/PDMR Shareholding
1st Oct 20257:00 amRNSTotal Voting Rights
22nd Sep 202512:48 pmRNSDirector/PDMR Shareholding- Replacement
22nd Sep 202511:52 amRNSDirector/PDMR Shareholding
22nd Sep 20257:00 amRNSFinancial results for the year ended 30 June 2025
5th Sep 202510:58 amRNSHolding(s) in Company
1st Sep 20257:00 amRNSNotice of year-end results
29th Aug 202511:07 amRNSHolding(s) in Company
12th Aug 20257:03 amRNSProposed acquisition of Conversia
12th Aug 20257:00 amRNSDirector Declaration
1st Aug 20257:00 amRNSAppointment of Joint Corporate Broker
30th Jul 20257:00 amRNSStatement in relation to a potential acquisition
23rd Jul 20257:00 amRNSTrading Statement
1st Jul 20257:00 amRNSTotal Voting Rights
26th Jun 20259:00 amRNSDirector/PDMR Shareholding
13th Jun 20257:00 amRNSTransaction in Own Shares
12th Jun 20257:00 amRNSTransaction in Own Shares
11th Jun 20257:00 amRNSTransaction in Own Shares
9th Jun 20257:00 amRNSTransaction in Own Shares
6th Jun 20257:00 amRNSTransaction in Own Shares
5th Jun 20257:00 amRNSTransaction in Own Shares
4th Jun 20257:00 amRNSTransaction in Own Shares
3rd Jun 20257:00 amRNSTransaction in Own Shares
2nd Jun 20259:30 amRNSTotal Voting Rights
2nd Jun 20257:00 amRNSTransaction in Own Shares
30th May 20257:00 amRNSTransaction in Own Shares
29th May 20257:00 amRNSTransaction in Own Shares
28th May 20257:00 amRNSTransaction in Own Shares
27th May 20257:00 amRNSTransaction in Own Shares
23rd May 20257:00 amRNSTransaction in Own Shares
22nd May 20257:00 amRNSTransaction in Own Shares
21st May 20257:00 amRNSTransaction in Own Shares
20th May 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.